



INNOVATING TO IMPROVE LIVES

CERTARA 2021 SUSTAINABILITY REPORT

Contents



INTRODUCTION

CEO Letter to
Our Stakeholders **3**

ESG Program Governance..... **4**

HEALTH AND SOCIAL IMPACT OF OUR SOFTWARE AND SERVICES

Overview **5**

R&D Investment and
Innovation..... **7**

Biosimulation Impact
in Oncology **8**

Biosimulation Impact on
COVID-19 **9**

OUR PEOPLE AND CULTURE

Our Cultural Values **10**

Engaging Our Employees..... **13**

Employee Health and
Wellbeing..... **14**

Community Impact..... **15**

Diversity, Equity and Inclusion... **16**

CORPORATE GOVERNANCE AND COMPLIANCE

Board of Directors **17**

Ethics and Compliance..... **20**

Data Privacy and
Cybersecurity..... **21**

Quality Products
and Services..... **24**

OUR ENVIRONMENTAL IMPACT

Overview **25**

Sustainable Procurement..... **26**

Introduction

CEO LETTER TO OUR STAKEHOLDERS

At Certara, our mission is to accelerate medicines to patients using biosimulation software, technology, and services. We inform critical decisions throughout the drug development process to not only deliver efficiencies but also to help increase drug safety and efficacy for the benefit of patients worldwide.

We tackle the toughest challenges in drug development with our cutting-edge technology and expert team of more than 1,100 employees worldwide. Our biosimulation software helps to predict how a drug works in different populations, such as infants, the elderly and people with co-morbidities. Biosimulation can be used to streamline clinical trials and enroll fewer patients. Certain studies, such as drug-drug interaction studies, may be waived altogether using our biosimulation software. With biosimulation, we can help to get safe and effective drugs developed and approved while minimizing testing of investigational drugs on animals and humans.

We also provide an integrated suite of technology-driven services, ranging from drug discovery and development to regulatory submission support and market access consulting. Our work spans a wide range of therapeutic areas from oncology to rare diseases and various modalities, including small molecules, biologics, and gene therapy. For the 8th consecutive year, our clients, who use our software and technology-driven services, received 90% of new drug approvals by the FDA, excluding diagnostics.

In the past two years, there has been no bigger challenge facing drug developers than combatting the COVID-19 pandemic. As many in the pharmaceutical industry shifted their focus towards COVID-19, we also dedicated resources to develop the Simcyp™ Vaccine Simulator and worked on 35 programs, from repurposed therapeutics and novel cocktail therapies to vaccines. Furthermore, we partnered with the Bill and Melinda Gates Foundation to launch covidpharmacology.com, providing biosimulation tools to drug developers to help optimize the design of clinical trials.

In 2021, Certara's Environmental, Social and Governance ("ESG") strategy focused on three key areas:

- **Accelerating crucial medicines to patients**

Accelerating medicines is our mission and why we are passionate about coming to work every day. Through our science-and-technology-based approach, we set precedents and expand boundaries in trusted collaboration with our customers. In 2021, we partnered with clients on more than 1,200 drug programs. We invested millions of dollars in R&D to innovate and expand use cases of biosimulation and regulatory technology.

- **Advancing scientific thought leadership and knowledge sharing**

Our expert global team not only contributes to software development and clients' drug programs, but also dedicates expertise and time to author publications and create and

deliver posters and presentations at conferences. In addition, Certara provides software licenses to hundreds of academic institutions worldwide for teaching purposes and academic research.

- **Increasing engagement with employees**

Our employees are our competitive advantage and create our success. With our growing global team and the challenges of the pandemic, we have made purposeful efforts to increase engagement with employees and provide support. We are deeply committed to providing flexibility and resources to help our team thrive at Certara.

While we are proud of the progress we have made in our first full year as a public company, we are excited about the road ahead as we continue to further our ESG initiatives. We believe that there is significant opportunity to continue expanding our positive impact worldwide. The pandemic has taught us that we can and must think differently about how we develop medicines, better and faster to improve and help save patient lives worldwide.



William F. Feehery, PhD
CEO



Introduction

ESG PROGRAM GOVERNANCE

CERTARA IS COMMITTED TO UNDERSTANDING, MONITORING, AND MANAGING OUR SOCIAL, ENVIRONMENTAL, AND ECONOMIC IMPACT TO SUPPORT SUSTAINABLE DEVELOPMENT.

This sense of corporate social responsibility manifests itself in several ways, including:

- Conducting our business in a responsible, honest, and ethical manner
- Acting as responsible stewards of the environment
- Ensuring a safe and healthy working environment for our employees
- Supporting universal human rights and
- Respecting and supporting the diverse cultures and individuals that form our Company.

Our Board of Directors, through the Nominating and Governance Committee, is ultimately responsible for our ESG strategy. The day-to-day management and implementation of our ESG programs are governed by our ESG Steering Committee. The ESG Committee supports the Company's on-going commitment to health and safety, corporate social responsibility, corporate governance, sustainability, charitable giving, environmental stewardship, and other public policy matters relevant to the Company. We reference and leverage sustainability standards applicable to our business, including the standards established by the Sustainability Accounting Standards Board ("SASB"), and incorporate the ten principles of the UN Global Compact into our ESG strategy.

The ESG Steering Committee is a cross-functional management committee, responsible for:

- Proposing general strategy relating to ESG matters
- Developing, implementing, and monitoring initiatives and policies based on that strategy
- Overseeing communications with employees, investors and stakeholders with respect to ESG matters
- Monitoring and assessing developments relating to, and improving the Company's understanding of ESG matters
- Providing efficient and timely disclosure of ESG matters to internal and external stakeholders.

The Committee currently consists of our Chief Human Resources Officer, General Counsel, Chief Strategy and Marketing Officer, and Vice President, Operations.

Health and Social Impact of Our Software and Services

OVERVIEW

\$28.1M

2021 R&D SPEND
(10% OF REVENUE)

10

NEW PRODUCTS AND
PRODUCT UPDATES IN 2021

1,200+

DRUG PROGRAMS ADVANCED
IN 2021

250+

REGULATORY SUBMISSIONS
IN THE PAST 4 YEARS

WE ACCELERATE MEDICINES TO PATIENTS USING OUR PROPRIETARY BIOSIMULATION TOOLS. Our biosimulation technology is a computer simulation of what happens when a dose of a drug is introduced to a human body. It is a large, complex model that captures the transport of the drug in the body, the concentration over time in places where you want the drug or where you may not want the drug and how it gets metabolized and excreted.

In SASB’s standards for the Biotech and Pharmaceutical sector, the safety of clinical trial participants is one key initiative. Our biosimulation software has many different uses throughout drug development to help increase safety and efficacy of drugs during their use in clinical trials and in the real world, post regulatory approval. For example, in the nonclinical phase, our biosimulation software with animal models for rat, mouse, dog and monkey, can be used to reduce animal testing. Then, before starting a Phase I trial, it is critical to determine the right “first in human” dose. This is typically informed by lab and animal trial data, but biosimulation can give a

more refined and accurate estimate on which to base the trial. In 2021, we conducted a first-in-human dosing workshop, teaching participants how to use models within the Simcyp Simulator to prioritize compounds for progress from nonclinical to Phase 1 clinical development using information available in early drug discovery.

As the drug moves into Phases 2 and 3, biosimulation is used to determine the right dose for the right patient. A dose that is too high could lead to side effects and safety issues. A dose that is too low may not be as effective as needed. Furthermore, biosimulation can streamline clinical studies, requiring fewer study subjects, and in some cases, biosimulation can waive a clinical study altogether, in particular drug-drug interaction studies.

Providing access to medicines is another top priority that we aim to achieve in two distinct ways. First, we can model pharmacological effects of a drug across many different human populations and profiles with our biosimulation software. There are certain populations that are much more challenging to enroll in clinical studies, such as

children and pregnant women. By being able to model how the drug works in virtual populations, we are able to predict the optimal dose for these special populations and inform the drug label. In 2021, our Simcyp Simulator was used to inform the drug labels of 13 novel drugs approved by the FDA. To date, we have informed more than 250 drug labels of 89 novel drugs approved by the FDA, helping to mitigate the cost and time required with clinical trials.

Additionally, with an estimated 2 billion people who do not have access to essential medicines, Certara along with others in the pharmaceutical ecosystem work together to expand access to much needed medicines in low- and middle-income countries. For example, we contributed to the TOGETHER study, a placebo-controlled, randomized, adaptive platform trial done among high-risk symptomatic adults confirmed positive for SARS-CoV-2 in Brazil. The study found that treatment with fluvoxamine, an affordable repurposed drug, among high-risk outpatients with early diagnosed COVID-19 reduced the need for hospitalization. Furthermore, in November 2021, we launched our Fellowship Program in Africa for

Health and Social Impact of Our Software and Services

OVERVIEW








Applied Pharmacometrics Training. This training program aims to build scientific and leadership capability in the region by enhancing the skills of scientists and facilitating knowledge transfer to wider scientific communities.

In later stages, biosimulation is frequently used in drug-drug interaction studies since we can use biosimulation to test many different combinations of drugs to determine which may cause adverse effects if taken together.

Biosimulation can also be instrumental in informing pediatric translational studies, in which our customers and we use data from adult clinical trials to predict the dose for children, from neonates to teenagers.

Our software portfolio also includes regulatory technologies, which help to increase the quality of and expedite patient safety narratives and other regulatory documents as well as the regulatory submission process. Regulatory requirements across countries and regions vary and are continuously evolving. The regulatory process requires significant effort and attention to detail. Non-compliance with regulatory standards or lack of quality can delay the approval process. At Certara, we have developed a suite of regulatory technologies that we and our clients use to save time and resources during regulatory preparation and submission.

SIMCYP SIMULATOR-SUPPORTED FDA APPROVED NOVEL DRUGS

| | | | | | | | |
|---|-------------------------------|---------------------|---|---------------------------|--|------------------|--|
|  | ONCOLOGY | Agios | Tibsovo (<i>ivosidenib</i>) | Genentech | Alecensa (<i>alectinib</i>) | Novartis | Odomzo (<i>sonidegib</i>) |
| | | Amgen | Blincyto (<i>blinatumomab</i>) | Genentech | Cotellic (<i>cobimetinib</i>) | Novartis | Piqray (<i>alpelisib</i>) |
| | | Ariad | Alunbrig (<i>brigatinib</i>) | Genentech | Polivy (<i>polatuzumab vedotin-piiq</i>) | Novartis | Rydapt (<i>midostaurin</i>) |
| | | Ariad (Takeda) | Iclusig (<i>ponatinib</i>) | Genentech | Rozlytrek (<i>entrectinib</i>) | Novartis | Tabrecta (<i>capmatinib</i>) |
| | | AstraZeneca | Calquence (<i>acalabrutinib</i>) | Incyte | Pemazyre (<i>pemigatinib</i>) | Novartis | Zykadia (<i>ceritinib</i>) |
| | | AstraZeneca | Lynparza (<i>olaparib</i>) | Janssen | Balversa (<i>erdafitinib</i>) | Pfizer | Bosulif (<i>bosutinib</i>) |
| | | AstraZeneca | Tagrisso (<i>osimertinib</i>) | Janssen | Erleada (<i>apalutamide</i>) | Pfizer | Lorbrena (<i>lorlatinib</i>) |
| | | Beigene | Brukisna (<i>zanubrutinib</i>) | Lilly | Retevmo (<i>selpercatinib</i>) | Pharmacyclics | Imbruvica (<i>ibrutinib</i>) |
| | | BluePrint Medicines | Ayvakit (<i>avapritinib</i>) | Lilly | Verzenio (<i>abemaciclib</i>) | Sanofi | Jevtana (<i>cabazitaxel</i>) |
| | | Celgene | Inrebic (<i>fedratinib hydrochloride</i>) | Loxo Oncology | Vittrakvi (<i>larotrectinib</i>) | Seattle Genetics | Tukysa (<i>tucatinib</i>) |
| | | Daiichi Sankyo | Turalio (<i>pexidartinib</i>) | Novartis | Farydak (<i>panobinostat</i>) | Spectrum | Beleodaq (<i>tucatinib</i>) |
| | | Eisai | Lenvima (<i>lenvatinib</i>) | Novartis | Kisqali (<i>ribociclib succinate</i>) | Takeda | Exkivity (<i>mobocertinib</i>) |
| | | EMD Serono | Tepmetko (<i>tepotinib hydrochloride</i>) | Novartis | Scemblix (<i>asciminib</i>) | Verastem | Copiktra (<i>duvelisib</i>) |
|  | RARE DISEASE | AkaRx (Eisai) | Doptelet (<i>avatrombopag maleate</i>) | Global Blood Therapeutics | Oxbryta (<i>voxelotor</i>) | Novartis | Isturisa (<i>osilodrostat</i>) |
| | | AstraZeneca | Koselugo (<i>selumetinib</i>) | Intercept | Ocaliva (<i>obeticholic acid</i>) | PTC Therapeutics | Emflaza (<i>deflazacort</i>) |
| | | Auriana | Lupkynis (<i>voclosporin</i>) | Kadman | Rezurock (<i>belumosudil</i>) | Sanofi Genzyme | Cerdelga (<i>eliglustat tartrate</i>) |
| | | Genentech | Enspryng (<i>satralizumab</i>) | Merck | Welireg (<i>belzutifan</i>) | Vertex | Symdeko (<i>tezacaftor/ivacaftor</i>) |
| | | Genentech | Evrysdi (<i>risdiplam</i>) | Mirum | Livmarli (<i>maralixiba</i>) | Vertex | Trikafta (<i>elexacaftor/ivacaftor/tezacaftor</i>) |
|  | CENTRAL NERVOUS SYSTEM | AbbVie | Rinvoq (<i>upadacitinib</i>) | Eisai | Dayvigo (<i>lemborexant</i>) | Lilly | Reyvow (<i>lasmiditan succinate</i>) |
| | | AbbVie | Qulipta (<i>atogepant</i>) | GW Research | Epidiolex (<i>cannabidiol</i>) | Novartis | Mayzent (<i>siponimod fumaric acid</i>) |
| | | Alkermes | Aristada (<i>aripiprazole lauroxil</i>) | Janssen | Ponvory (<i>ponesimod</i>) | UCB | Briviact (<i>brivaracetam</i>) |
| | | Alkermes | Lybalvi (<i>olanzapine; samidorphan</i>) | Kyowa Kirin | Nourianz (<i>istradefylline</i>) | | |
|  | INFECTIOUS DISEASE | Gilead | Veklury (<i>remdesivir</i>) | Merck | Prevymis (<i>letermovir</i>) | Tibotec | Edurant (<i>rilpivirine</i>) |
| | | GSK | Dectova (<i>zanamivir</i>) | Nabriva | Xenleta (<i>lefamulin acetate</i>) | VIIV | Cabenuva Kit (<i>cabotegravir, rilpivirine</i>) |
| | | Janssen | Olysio (<i>simeprevir</i>) | Novartis | Egaten (<i>tricitabendazole</i>) | VIIV | Vocabria (<i>cabotegravir sodium</i>) |
| | | Merck | Pifeltro (<i>doravirine</i>) | | | | |
|  | GASTROENTEROLOGY | AstraZeneca | Movantik (<i>naloxegol</i>) | Shionogi | Symproic (<i>naldemedine</i>) | Shire | Motegrity (<i>prucalopride</i>) |
| | | Helsinn | Akynzeo (<i>fosnetupitant/palonosetron</i>) | | | | |
|  | CARDIOVASCULAR | Actelion (J & J) | Opsumit (<i>macitentan</i>) | Johnson & Johnson | Xarelto (<i>rivaroxaban</i>) | Pfizer | Revatio (<i>sildenafil</i>) |
|  | OTHER | AbbVie | Orilissa (<i>elagolix</i>) | Janssen | Invokana (<i>canagliflozin</i>) | Merck | Steglatro (<i>ertugliflozin</i>) |
| | | Galderma | Aklief (<i>trifarotene</i>) | Lilly | Olumiant (<i>baricitinib</i>) | | |

Health and Social Impact of Our Software and Services

R & D INVESTMENT AND INNOVATION

WE INVESTED \$28.1M IN R&D OR 10% OF OUR REVENUE IN 2021, RESULTING IN THE LAUNCH OF 2 NEW SOFTWARE PRODUCTS AND UPDATES TO 8 SOFTWARE APPLICATIONS. With approximately 150 software developers and technology experts at Certara worldwide, we have a regular cadence of product releases that deliver new capabilities and expand use cases to accelerate our clients' drug development programs and impact patient lives.

In 2021, we launched our Secondary Intelligence™ software, the only software currently available that quantitatively predicts the risk of adverse effects and safety issues derived from secondary pharmacology that may impede the clinical development of a drug. Safety issues account for approximately one quarter of candidate attrition in drug development projects. They can arise from either intended or unintended drug-receptor interactions, also known as primary or secondary pharmacology, respectively. The current process for analyzing secondary pharmacology is manual, which can lead to inefficiencies and inconsistencies. Secondary Intelligence provides automated intelligence and turnkey insights so that safety pharmacologists and toxicologists

can make faster, more confident go/no go portfolio decisions earlier in the drug discovery and development process.

We also launched the first release of Synchronix Writer™ in 2021. Synchronix Writer is a new regulatory SaaS product that expedites the authoring and review of patient narratives. Patient narratives describe adverse events or adverse drug reactions and are critical to clinical study reporting across every therapeutic area. The traditional, manual narrative writing process is time-consuming and costly due to integration of information from various sources, large authoring teams, and multiple rounds of drafting and reviews.

Spearheaded by Certara's regulatory writing experts, Synchronix Writer software automates data-mapping and enables earlier drafting before database lock. With Synchronix Writer, organizations can manage thousands of patient narratives in a fraction of the time while ensuring quality, consistency, and compliance. In 2021, Certara's regulatory science team has already used Synchronix Writer to deliver 5,000 patient safety narratives for sponsors.



“Synchronix Writer has truly changed the writing process for safety narratives. Our team is able to synthesize safety information efficiently while collaborating with sponsors to expedite timelines and increase consistency, ultimately assuring quality in the drug approval process.”

Gabriella Mangino, Product Manager

Health and Social Impact of Our Software and Services

BIOSIMULATION IMPACT IN ONCOLOGY

WITH NEARLY 40% OF THE GLOBAL R&D PIPELINE FOR THERAPEUTICS DEDICATED TO ONCOLOGY, it is no surprise that Certara contributed to advancing numerous oncological programs, including 6 novel drugs for cancer approved by the FDA in 2021.

We have invested in biosimulation software specifically for immuno-oncology. In 2021, we launched Version 3.0 of our Immuno-oncology (“IO”) Quantitative Systems Pharmacology (“QSP”) Simulator. In immuno-oncology, the sheer number of possible therapy combinations requires a quantitative framework


to integrate the complex and dynamic factors that determine efficacy and historically have led to the selection of suboptimal combinations. Certara’s IO Simulator uses virtual patients to quickly test these different combinations to determine the optimal combination of therapies and dosing regimens. The latest version of the IO Simulator vastly expands the number of targets and cell types including cytokines, immune cell types, and tumor neoantigens. It can also test combinations of chemotherapy and radiotherapy. The IO Simulator has correctly predicted therapeutic outcomes of using drugs in various cancer types, including solid tumors and blood cancers.

Our drug development consulting, regulatory and market access teams worked on more than 1,200 active projects for clients in 2021. Oncology programs make up our largest therapeutic category of our services work. One innovative project we contributed to recently was a CAR T-cell therapy for large B-cell

Our drug development, regulatory and market access teams worked on more than 1,200 client projects in 2021.

lymphoma. Certara developed a population cellular kinetic model to characterize the kinetics of the therapy and understand how covariates might impact kinetics in individual patients. The biosimulation analysis found that the covariates tested were not considered to have a meaningful impact on kinetics of the therapy. Thus, dose adjustments were not needed for specific populations.

In 2022, we anticipate our work in oncology to grow with the recent launch of FDA’s Project Optimus initiative. Traditionally, the maximum tolerated dose approach has been used for oncology first-in-patient studies, and it is often taken forward in subsequent studies. However, poorly characterized dose and schedule may lead to selection of a dose that provides more toxicity without additional efficacy. With Project Optimus, the FDA is reforming the dose optimization and dose selection paradigm in oncology drug development. This new regulatory change may impact time and cost of oncology drug development programs. Biosimulation can be a valuable tool in studying different dosing strategies using virtual patients to determine the optimal dosing regimen.



Health and Social Impact of Our Software and Services

BIOSIMULATION IMPACT ON COVID-19

The COVID-19 pandemic is the most catastrophic, global public health crisis of this century. Along with many others in the pharmaceutical industry, Certara heeded the call to action and dedicated effort to fight this devastating infectious disease.

WE WORKED WITH 35 DIFFERENT PARTNERS TO SUPPORT DRUG AND VACCINE DEVELOPMENT AND REGULATORY STRATEGY AND SUBMISSIONS.

Early in the pandemic, we partnered with the Bill and Melinda Gates Foundation and used biosimulation to help determine which on-market drugs could be repurposed to create safe and effective treatments for COVID-19. Biosimulation is a particularly powerful approach in this case, because it allows existing drugs and drug combinations to be tested in computer-based trials using virtual patients before biopharmaceutical companies progress to human clinical studies. Our modeling and simulation also provided support to help eliminate existing drugs that were promoted for off-label use as COVID-19 therapies, such as ivermectin and hydroxychloroquine. In this instance, we used biosimulation to determine which drugs could reach a therapeutic dose in the lungs; explore potential drug-drug interactions; and identify the optimal drug dose and regimen for use in clinical trials. This approach also enables drug dosing to be optimized for different populations, such as pediatric and geriatric patients, pregnant women, and those with pre-existing conditions.

We also developed the CODEx COVID-19 Clinical Outcomes Database, which documents clinical safety and efficacy information from studies investigating treatments and emerging interventions for COVID-19. It captures all important aspects of reference information, study design, patient population characteristics, randomized and concomitant treatments, statistical analyses and results. The complete database currently contains summary level endpoint data from 610 studies. Researchers have access to this database for a nominal fee to cover the cost of supporting ongoing maintenance of the database. Researchers analyze the data to derive insights on which therapies work better for whom and understand the interplay between real world studies and randomized controlled trials to streamline drug repurposing for pandemic viral disease.

Starting in 2020, we invested in developing our Simcyp COVID-19 Vaccine Model, which has been used to improve decision-making and help optimize dosing regimens for COVID-19 vaccines. Certara's COVID-19 Vaccine Model determines how a vaccine is handled by the human body using computer-generated, virtual populations with different ages, gender, weight, genetics, diet, illnesses, and medications. The model employs those virtual populations in virtual clinical trials and the results are used to optimize treatment regimen for COVID-19 vaccines and to predict

duration of antibody responses. This model allows virtual COVID-19 vaccine trials to be conducted much faster and at lower cost than live clinical studies. It also facilitates virtual trials that may be impractical or unethical to perform with real participants. Certara's Simcyp COVID-19 Vaccine Model has demonstrated that it can accurately predict the outcomes of actual clinical trials of COVID-19 vaccines using virtual patients. Its prediction that the optimal timing between the first two COVID-19 vaccine doses is eight weeks was validated by the Pitch study conducted at Oxford University. We calibrated our model using COVID-19 vaccine structures and validated it by replicating the published clinical data. Furthermore, results from the model have been presented by companies developing COVID-19 vaccines at the American College of Clinical Pharmacy and American Association of Pharmaceutical Scientists as well as to global regulatory agencies, including the US FDA.

Acknowledging the importance and benefits of this technology, our Simcyp COVID-19 Vaccine Model has been named a winner of the R&D World's 2021 R&D 100 Awards in the Software/Services category, a finalist in the 2022 Edison Awards, and a finalist in Informa Pharma Intelligence's 2021 Citeline Awards in the Excellence in Innovation in Response to COVID-19 - Clinical Trial Activities category.

Our People and Culture

OUR CULTURAL VALUES


IN THE
top 25%
 IN ENGAGEMENT EMPLOYEE NET PROMOTER SCORE AMONG LIFE SCIENCE COMPANIES IN 2021

150+
 SCIENTIFIC PUBLICATIONS, POSTERS AND PRESENTATIONS IN 2021

3,000+
 SCIENTISTS TRAINED IN OUR SOFTWARE IN 2021

“Every day and in everything we do, we embrace idea generation, trust and support each other to think creatively and work together to improve the lives of patients everywhere.”

– William Feehery, CEO



At Certara, we recognize that our success would not be possible without the valuable contributions of our workforce. As such, **WE ARE COMMITTED TO INVESTING IN OUR PEOPLE AND FOSTERING AN ENGAGED WORKFORCE** that exemplifies some of our cultural tenets of innovation, collaboration, customer impact and scientific excellence.

INNOVATION

Certara is at the forefront of innovation in science and technology with a long history of firsts led by our team of experts, who are passionate about improving and accelerating the drug development process. Certara has more than 350 employees who hold doctorate degrees – PhDs, PharmDs and MDs. We highly value scientific curiosity, method, and rigor. Certara actively encourages curiosity and innovation through multidisciplinary work teams of scientists, modelers, mathematicians, regulatory experts and developers working together on research and software projects.

For example, the FDA published a manuscript in 2021 on how the Simcyp’s Mechanistic Dermal Absorption (MechDerma™) model was used to support bioequivalence and the approval of diclofenac sodium topical gel. This was the first FDA approval for a complex generic using virtual bioequivalence, waiving a human clinical trial and thereby saving significant time and money. Demonstrating bioequivalence is especially complex for topical, dermatological generic treatment, so generic products are challenging to bring to market, impacting patient access. The FDA has directed research initiatives aimed at reducing barriers that may adversely impact patient access to dermatological drug products. In 2021, Certara was awarded our fourth grant by the FDA to further develop our MechDerma model. We continue to invest in expanding biosimulation models for assessing virtual bioequivalence to help enable safer, faster and more cost-effective generic drug product development.

As a company with a rich scientific heritage and culture, our staff is committed to sharing lessons learned and best practices with each

Our People and Culture

OUR CULTURAL VALUES

other and the industry. We are all innovators at Certara, no matter what our roles, and we address challenges with an innovative mindset and actively foster a culture that supports the application of new ideas. Our people enjoy the scientific freedom to explore novel ideas, develop groundbreaking research, and act as leaders in the scientific community. As a result, Certara has an exceptional presence at major scientific conferences, participating in presentations and poster sessions, exhibiting and sponsoring events.

In 2021, our commitment to moving the entire industry forward was exemplified through our contribution to more than 150 scientific publications and presentations at key industry conferences, as well as hosting 48 scientific webinars and over 15,000 attendees and recording views. Our staff participated in approximately 40 annual scientific conferences, contributing to as many as 28 sessions at a single event, and in 2021, more than 3,000 scientists were trained in our software. Certara provides an annual training budget to enable our people to further their professional development and creative mindset by attending pertinent conferences, even when not presenting.

We have also established a Journal Club where our scientists can discuss manuscripts with their peers. The Journal Club further exemplifies the value we place on innovation by actively involving Certara scientists in the broader research community, expanding their professional networks and fueling their scientific curiosity.

"Encouraging employees to share their knowledge at conferences and through scientific publications is a top priority at Certara. Knowledge sharing among our experts, partners and the industry harnesses our collective expertise to solve the most complex problems in drug development."



– Nicolette Sherman, Chief Human Resources Officer

COLLABORATION

Certara's culture encourages camaraderie and collaboration. Our staff endeavors to make new employees part of our team right from the start. We have developed manager onboarding specifically for this purpose, and we guide new employees with activities in preparation for their arrival and then align on goals for their orientation day, first week and first 60 days. Our onboarding also outlines the advantages of mentoring and provides new employees with a mentor to help them get guidance during this crucial learning phase.

We also value having approachable senior managers and human resources staff to build our culture and support our employees with day-to-day issues. Our priority is to build strong relationships across our employee base and ensure that all employees have the support

and resources needed to succeed and achieve high levels of engagement. With our digital learning library, employees have access to a variety of courses, in addition to our broader offerings, to support their overall wellbeing, enhance their sense of connectedness, and foster continued personal and professional development.

CUSTOMER IMPACT

Certara provides employees with a broad range of collaborative customer experiences. For example, our Simcyp R&D team runs consultancy projects and provides workshops and training classes, participates in grant writing, and interacts with clients through our industry consortia. Underscoring this point, Certara is the founder of three industry consortia in which biopharmaceutical companies collaborate in a pre-competitive environment to develop best practices and progress modeling and simulation.

The Simcyp Consortium, which was formed more than 20 years ago, now has 37 leading biopharmaceutical companies as members and is a global authority on mechanistic, physiologically-based pharmacokinetic ("PBPK") modeling and simulation. The member companies work together to progress model-informed drug development and inform the annual updates and new features to Certara's Simcyp PBPK Simulator. Eleven leading regulatory agencies, including the FDA and Japan's Pharmaceuticals and Medical Devices Agency, have also adopted the Simcyp Simulator. To date, Simcyp

Our People and Culture

OUR CULTURAL VALUES

Simulator modeling and simulation has informed more than 250 label claims for 89 novel drugs approved by the FDA, without the need for clinical trials. Certara's Simcyp Consortium proved so successful that it became the model for two additional pre-competitive consortia. Certara is now working with leading biopharmaceutical companies to develop immunogenicity and immuno-oncology models.

The Immunogenicity Consortium members set out to build a mechanistic model of the human immune system because they wanted to be able to predict when administering a biological therapeutic, such as an antibody, would generate an undesired immunogenic response. Immunogenicity is a challenge for biologic therapies, because it can cause adverse events. This work underscores how Certara prioritizes customer impact and serves as a reminder that we must always work to address even the broadest and most challenging therapeutic obstacles.

SCIENTIFIC EXCELLENCE

At Certara, scientific excellence is in our DNA. It guides our purpose of transforming drug development through unparalleled science, software and services and fuels our mission of "Accelerating Medicines Together."

We were honored to have 7 of our Certara scientists recognized in the top 2% of cited scientists based on standard citation metrics published by Elsevier and Stanford University in 2021. In further

support of building scientific excellence for future generations, Certara hosts an annual Simcyp Scientific Academic Awards program, which celebrates the Simcyp Simulator's effective use in research and in teaching new scientists. More than 100 academic institutions use the Simcyp Simulator for biosimulation teaching and research, so it is a very competitive program. Awards are given for the Most Informative Scientific Report and Most Effective Teaching Application. Eligible institutions can also apply for funding for a research project through Certara's Grant and Partnership Scheme, which covers either a PhD or post-doctoral research program every year. Certara staff also continuously liaise with the winning organization on training and research.

To help ensure that biosimulation research advances are not limited by resources, Certara provides 100 academic and non-profit organizations with more than 2,000 complimentary licenses to our Simcyp Simulator, as well as licenses to Phoenix. Certara also finds other ways to support new scientists, such as helping to fund the Population Approach Group in Europe Student Sponsorship, which enables student presenters at the PAGE Annual Meeting to attend the conference. Furthermore, we launched the Certara New Investigator Awards in association with the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists to recognize graduate investigators who are excelling in clinical and experimental pharmacology and toxicology and support scientific excellence.

Certara has collaborated with scientists in the US, UK, China, Japan, and the Netherlands to create 9 Academic Centers of Excellence to teach the next generation of pharmaceutical scientists. Certara provides faculty, students, and post-doctoral researchers at each Center of Excellence with Phoenix software licenses at no cost to support their coursework, academic research, and collaboration on projects with Certara. The Centers of Excellence then share the resulting research with the industry.

Through its Certara University, the Company teaches a roster of live online, on-demand, and in-person courses for new and advanced users of our Phoenix software. In 2018, we introduced a Professional Certification Program for users who want to have their proficiency and expertise in Phoenix software validated. Additionally, we have a certification program for our BaseCase value communication software, which enables our customers to better communicate the value of their novel therapies to healthcare payers and providers.

Certara's cultural tenets fuel our mission of Accelerating Medicine to Patients by creating a sense of global togetherness within our Company and across the broader scientific community. Building connections and fostering innovation across the entire scientific community gives the world the best chance of innovating to save lives and preventing patient suffering. That is what Certara is all about, and we are driven to succeed.

Our People and Culture

ENGAGING OUR EMPLOYEES

WE RECOGNIZE THAT DRIVING OUR CULTURE, LIVING OUR VALUES AND ENGAGING OUR PEOPLE ARE ESSENTIAL FOR GROWTH IN A RESEARCH-BASED ORGANIZATION. In 2021, Certara conducted an annual all-employee engagement survey to gauge employee sentiment and identify opportunities for improvement. This survey and the follow-up actions that accompany it are critical to maintaining a comprehensive understanding of employee engagement and ensuring

that Certara employees feel connected to the Certara mission and empowered to build long-lasting, fulfilling careers within the organization.

In addition to facilitating two-way dialogue with employees, another important goal we have is to be in the top quartile of our industry benchmark. With an Engagement employee net promoter score (“eNPS”) of 44, we are proud to report that in 2021 we are in the top 25 percent of all healthcare, pharmaceutical/biotech and life sciences companies that collect eNPS scores, despite the challenges that the COVID-19 pandemic brought to the world of work. Our Diversity and Inclusion eNPS is at 38, and our Health and Wellbeing eNPS is at 35, both in the mid-range of the sector data. As we continue to respond to the voice of our employees and the feedback that they are providing, our goal is to continuously improve engagement with employees.



Certara was named one of the top 10 best places to work in New Jersey in 2021 by NJBIZ magazine.

This prestigious award recognizes employers with exceptional employee engagement and whose employees have highly favorable views regarding company practices and culture. It is especially meaningful as our global headquarters are in Princeton, New Jersey.

Our People and Culture

EMPLOYEE HEALTH AND WELLBEING

CERTARA TAKES A HOLISTIC APPROACH TO EMPLOYEE HEALTH AND WELLBEING

and offers a multitude of benefits and programs to support employees.

Certara provides a very competitive compensation package, which includes (depending on location) pension/retirement savings benefits, life insurance, income protection, healthcare, and gym payments. In addition, we offer at least 25 days of vacation outside the US, plus national holidays, and a generous sickness policy. Absence is proactively managed with a return-to-work mindset, but illness occurs, and employees are supported through it. In the US, Certara has an unlimited vacation policy. Certara also provides financial support for maternity and paternity leave and assistance to new mothers returning to work.

The Company also offers global health and welfare plans, ensuring that all our employees receive coverage. While there is some variation by region and country, Certara provides a competitive benefits program in each market. Certara also has a global employee assistance program that provides access and support for employees on a wide variety of topics. This program offers confidential assessments, counseling, referrals, and follow-up services to employees needing support. Additionally, two team

members are certified mental health responders through the National Council for Mental Wellbeing.

In early March 2020, we instituted a global work-from-home policy to ensure the health of our employees and local communities during the COVID-19 pandemic. As a result, all employees transitioned to working from home, and we began providing virtual wellness and mental health support programs, such as virtual fitness challenges, hydration challenges, live and on-demand yoga, and meditation classes. These offerings are featured, along with other global employee resources, on the Certara Wellness & Lifestyle website.

Our staff is also well-equipped to work remotely while engaging with our customers and advancing business objectives. As the pandemic continues, many employees have adopted a hybrid schedule, working part-time in the office and part-time remotely. All employees that have returned to the office have completed re-entry training on safety and reporting protocols to ensure that they remain healthy.

To help employees feel connected and supported while working from home, Certara has organized regular meetings with colleagues overseas. These

virtual get-togethers have included coffee meetings, team-building events, a recipe exchange, and a holiday party where employees decorated gingerbread houses.



Our People and Culture

COMMUNITY IMPACT

CERTARA EMPLOYEES ARE COMMITTED TO GIVING BACK TO THE COMMUNITIES where they live and work in creative ways, which leverage their skills and strengths.

To help get children interested in science, technology, engineering, and mathematics (STEM) careers from an early age, we participate in a pen pal program called "Letters to a Pre-Scientist," which pairs employees with 5th to 10th grade students in low-income communities. Through this letter-writing program, we inspire and empower students to pursue their own STEM careers. Certara also hosts work experience weeks for local school children who would like to gain hands-on industry experience in science and software development.

Certara employees also conduct presentations and participate in recruitment fairs at local universities to encourage students to embark on drug development and regulatory careers.

Instead of giving holiday gifts during the pandemic, Certara's Software Division chose charities that were close to four of its offices and gave donations on its employees' behalf. **In keeping with the company's focus, they selected organizations that help improve the health and wellbeing of their local community.**



Our People and Culture

DIVERSITY, EQUITY AND INCLUSION

CERTARA'S INNOVATIVE CULTURE IS GROUNDED IN RESPECT FOR DIVERSE IDEAS AND PERSPECTIVES AND ADVANCEMENT OF DIVERSITY, EQUITY, AND INCLUSION. We promote a positive and productive work environment free from discrimination, harassment, and retaliation, and where everyone is treated fairly and with dignity and respect. To help achieve that goal, all Certara employees participate in unconscious bias training as part of the Company's new hire compliance curriculum.



Certara ensures that all staff have equal opportunities for career advancement. To this end, all promotion opportunities are posted and announced openly, and pay is reviewed regularly to ensure fair practices. Furthermore, job training programs covering technical and soft skills are available on an ongoing basis for employees who want to refine specific skills. In addition, all employees participate in a formal performance management process and receive career coaching and counseling as necessary.

Certara staff who participate in screening and selecting new hires receive ongoing training to maintain and improve those nondiscriminatory practices, including participating in biannual Office of Federal Contract Compliance / Local Job Network training. Additionally, Certara has developed several recruitment programs in the US to attract diverse applicants, including females, minorities, veterans, and individuals with disabilities.

Certara also encourages minority and female employees to refer job applicants. Applications from minorities and women are also encouraged during school recruiting efforts. We embrace diversity and strive to include our own Certara employee photos in recruiting brochures and on career pages to highlight the Company's diverse culture. In addition, new job openings are advertised in publications written for minority groups and women.

GENDER AND ETHNICALLY DIVERSE REPRESENTATION

GLOBAL FEMALE TALENT REPRESENTATION



| | FY20 | FY21 |
|----------------------------------|------------|------------|
| FEMALE EMPLOYEES | 52% | 54% |
| FEMALE MANAGERS AND ABOVE | 46% | 48% |
| FEMALE NEW EMPLOYEE HIRES | 55% | 60% |

U.S. ETHNICALLY DIVERSE TALENT REPRESENTATION



| | FY20 | FY21 |
|--|------------|------------|
| ETHNICALLY DIVERSE | 27% | 28% |
| ETHNICALLY DIVERSE MANAGERS AND ABOVE | 22% | 22% |
| ETHNICALLY DIVERSE NEW EMPLOYEE HIRES | 34% | 35% |

Corporate Governance and Compliance

BOARD OF DIRECTORS

Certara’s board of directors is responsible for overseeing the activities and affairs of the Company, as reported to the board by our CEO and senior management team.

BOARD OVERSIGHT OF ESG MATTERS

The board ensures that the Company is committed to and is pursuing activities that support responsible ESG policies. The board has delegated the primary oversight of ESG matters to the Nominating and Corporate Governance Committee, who works with senior management, through our ESG Steering Committee, to develop and implement a long-term ESG strategy.

BACKGROUND AND EXPERIENCE OF DIRECTORS

Our board members have been selected based on their qualifications, strength of character, judgment, industry knowledge and experience. When considering new nominees, in addition to those qualities, the board considers other factors, including age, diversity of background, existing commitments to other businesses, service on other boards of director or similar governing bodies of public or private companies, potential conflicts of interest, corporate governance background, financial

and accounting background, executive compensation background, and the overall size, composition and combined expertise of the exiting board of directors. We believe that our directors provide an appropriate mix of experience and skills relevant to the size and nature of our business. Once appointed, directors serve until their term expires, they resign, or they are removed by the stockholders.

BOARD STRUCTURE

Our board of directors currently consists of ten individuals, divided into three classes of directors, with staggered three-year terms. One class of directors is elected at each annual meeting of stockholders. The board meets regularly with senior management,

typically 4-5 times per year, in addition to special ad hoc meetings that may be called from time to time by either the chairman of the board or as requested by our CEO.

Our leadership structure separates the offices of chief executive officer and chairperson of the board of directors, with Dr. William Feehery serving as our CEO and Mr. James Cashman serving as chairman of the board. We believe this is appropriate as it provides Dr. Feehery with the ability to focus on our day-to-day operations while allowing Mr. Cashman to lead our board of directors in its fundamental role of providing advice to and oversight of management.

Our board of directors has no firm policy with respect to the separation of the offices of CEO and chairperson of the board of directors. It is the board of directors’ view that rather than having a rigid policy, the board, upon consideration of all relevant factors and circumstances, will determine whether the two offices should continue to be separate. We do have a policy that if the chairperson of the board is also the chief executive officer or is a director who does not otherwise qualify as an “independent director,” the independent directors will elect from among themselves a Lead Director of the board.

BOARD DEMOGRAPHICS ON GENDER



Corporate Governance and Compliance

BOARD OF DIRECTORS

COMMITTEES OF THE BOARD OF DIRECTORS

The standing committees of our board of directors consist of an Audit Committee, a Compensation Committee and a Nominating and Corporate Governance Committee. Our chief executive officer and other executive officers regularly report to the non-executive directors and the Audit, the Compensation and the Nominating and Corporate Governance Committees to ensure effective and efficient oversight of our activities and to assist in proper risk management and the ongoing evaluation of management controls.

COMPENSATION COMMITTEE

The purpose of the Compensation Committee is to assist our board of directors in discharging its responsibilities relating to, among other things, (1) setting our compensation program and compensation of our executive officers and directors, including reviewing the Company's efforts with respect to pay equity, (2) administering our incentive and equity-based compensation plans and (3) preparing the compensation committee report required to be included in our proxy statement under the rules and regulations of the SEC.

NOMINATING AND CORPORATE GOVERNANCE COMMITTEE

In addition to overseeing the Company's ESG programs and strategies, the purpose of our Nominating and Corporate Governance Committee is to assist our board of directors in discharging its responsibilities relating to (1) identifying individuals qualified to become new board members, consistent with criteria approved by the board of directors, (2) reviewing the qualifications of incumbent directors to determine whether to recommend them for reelection and selecting, or recommending that the board of directors select, the director nominees for the next annual meeting of stockholders, (3) identifying board members qualified to fill vacancies on any committee of the board of directors and recommending that the board of directors appoint the identified member or members to the applicable committee, (4) reviewing and recommending to the board of directors corporate governance principles applicable to us, and (5) overseeing the evaluation of the board of directors and management.



Corporate Governance and Compliance

BOARD OF DIRECTORS

AUDIT COMMITTEE

The purpose of the Audit Committee is to prepare the audit committee report required by the SEC to be included in our proxy statement and to assist our board of directors in overseeing and monitoring (1) the quality and integrity of our financial statements, including oversight of our accounting and financial reporting processes, internal controls and financial statement audits, (2) our compliance with legal and regulatory requirements, (3) our independent registered public accounting firm's qualifications, performance and independence, (4) our corporate compliance program, including our code of conduct and anti-corruption compliance policy, and investigating possible violations thereunder, (5) our risk management policies and procedures, including those relating to data privacy and protection and cybersecurity and (6) the performance of our internal audit function.

DIRECTOR INDEPENDENCE

Our board of directors has affirmatively determined that each of our directors, other than our CEO, Dr. Feehery, qualifies as

"independent" in accordance with SEC guidance and Nasdaq rules. Our Audit Committee members also qualify as independent under the heightened standard of independence for Audit Committee members. In making its independence determinations, our board of directors considered and reviewed all information known to it, including information identified through directors' questionnaires.

CORPORATE GOVERNANCE GUIDELINES

Our board of directors has adopted corporate governance guidelines which describe the principles and practices that our board of directors will follow in carrying out its responsibilities. These guidelines cover a number of areas including the role and responsibilities, size and composition of the board, independence of directors, selection of chairperson of the board and chief executive officer, conflicts of interest, change in present job responsibility, director orientation and continuing education, lead director, term limits, board meetings, board committees, expectations of directors, management succession planning, evaluation of board performance, board compensation, communications with stockholders, implementation of

stockholder agreements, and communications with non-management directors.

Our board of directors has also implemented a Delegation of Authority policy to clearly delineate the day-to-day activities that may be performed and executed by senior management from more material or strategic decisions that require prior notice and approval by the board of directors.

STOCK OWNERSHIP REQUIREMENTS

To further align the interests of our board members with the interests of our stockholders, our board of directors has adopted director stock ownership guidelines for non-employee directors. Each non-employee director who receives a cash and/or stock retainer for his or her service as a director has a target minimum common stock ownership requirement of five times the value of the annual cash retainer (excluding committee retainers) paid by us to the non-employee director pursuant to our then current director compensation plan. Non-employee directors are expected to meet this minimum target within five years of becoming subject to the ownership guidelines.

Corporate Governance and Compliance

ETHICS AND COMPLIANCE

WE HAVE ADOPTED A CODE OF CONDUCT THAT APPLIES TO ALL EMPLOYEES, EXECUTIVE OFFICERS AND DIRECTORS, addressing legal and ethical issues that may be encountered in carrying out their duties and responsibilities, including the requirement to report any conduct they believe to be a violation of the Code of Conduct. Our Code of Conduct covers a wide range of ethical and legal issues, including business conduct, conflicts of interest, record keeping, confidentiality, discrimination and harassment, health and safety, and

fair competition, among other topics. We require all new employees to review and understand the Code of Conduct and regularly conduct training for all employees on our Code of Conduct.

We encourage all of our employees to ask questions, raise concerns, or report misconduct, through a number of avenues, including use of our compliance hotline, and we have a strict non-retaliation policy.

In addition to our Code of Conduct, we have adopted a number of other related policies, including our policies on Anti-Bribery/Corruption, Anti-Harassment and Discrimination, Quality, Insider Trading, External Communication, Data Privacy and Protection, Environmental Stewardship, and Sustainable Procurement, and have adopted a separate Human Rights Statement.

99%


TRAINING OF ALL EMPLOYEES ON CODE OF CONDUCT



TOPICS THAT EMPLOYEES RECEIVE REGULAR TRAINING ON

In addition to Code of Conduct training, our employees receive regularly training on the following areas:

- Insider trading
- Global anti-corruption and anti-bribery
- Unconscious bias
- IT security
- Data protection basics
- Data security for teleworkers
- Recognizing and avoiding social engineering
- Harassment prevention



Corporate Governance and Compliance

DATA PRIVACY AND CYBERSECURITY

CERTARA IS COMMITTED TO PROTECTING THE PRIVACY AND SECURITY OF THE PERSONAL INFORMATION THAT WE COLLECT OR USE WHILE DOING BUSINESS.

We do so in accordance with all applicable data protection and privacy laws, rules and regulations, and regulatory guidance, guidelines, and requirements in the jurisdictions where our services are rendered and/or the parties are based.

We have operationalized data privacy, security, and compliance to build digital trust. We have established a comprehensive Data Security and Privacy Program and governance model to achieve that goal, which allows us to respond rapidly with new policies, processes, or applications to meet changing needs or regulations.

DATA PRIVACY AND SECURITY GOVERNANCE

Our data security and privacy program is headed by Certara's Security and Privacy Program Office ("SPPO"), which is composed of corporate leaders from our legal and IT teams. They are responsible for the program's strategy, design, execution, and reporting.

The SPPO reports to our Security and Privacy Steering Committee ("SPSC"), which is comprised of functional and business unit executive leaders, and provides governance, oversight, and resources for Security and Privacy Program activities. The SPSC is responsible for ensuring that Certara complies with security and privacy regulations and controls and provides regular updates to the Audit Committee of our board of directors.

PROGRAM STRUCTURE

Certara's Security and Privacy Program ensures that information assets are protected from threats, whether internal or external, deliberate or accidental.

We use a third-party privacy, security, and data governance platform to evaluate our privacy impact assessments and our processes and have conducted a data mapping inventory of our processes, vendors, and assets. We also manage data participant requests through that system.

Certara's Security and Privacy Program follows the National Institute of Standards and Technology ("NIST") Risk Management Framework, the NIST Cybersecurity Framework, and the NIST Privacy Framework.



"Data protection and cyber security are important areas that we prioritize and manage proactively. As a testament to the success of our program, we have not experienced any reportable data breaches."

– Leif Pedersen, President of Software

Corporate Governance and Compliance

DATA PRIVACY AND CYBERSECURITY

1

PERSONAL DATA LIFECYCLE MANAGEMENT

Certara limits the collection, creation, use, dissemination, maintenance, retention, and/or disclosure of personal data to those that are legally authorized, relevant, and deemed "reasonably necessary" for the proper performance of our business. We maintain appropriate technical and organizational measures to keep personal information secure and protect against unauthorized or unlawful processing and against accidental loss, destruction, or damage. Personal information (and sensitive personal information) is only retained for the period that is necessary to perform the required function and comply with data protection laws and Certara's contractual obligations.

2

PRIVACY CHOICES AND DATA PARTICIPANT RIGHTS/REQUESTS

Certara allows individuals to choose how their personal data are handled as required by applicable data protection and privacy laws and regulations for the locations where we conduct business. Individuals have the following choices and rights regarding their personal data that we collect and process: right of access, accuracy, erasure, and portability. They also have the right to restrict processing, object or opt-out.

3

TRANSPARENCY AND PRIVACY NOTICES

We communicate transparently with all data participants about our privacy practices, including gaining active consent from people when their personal data are collected. We declare the lawful basis for collection, use, maintenance, and sharing of personal data. This includes staff documentation and public notices on all our websites, mobile applications, and other digital services regarding the collection, creation, use, dissemination, maintenance, retention, onward transfer and/or disclosure of personal data. [Link to our privacy notice.](#)

4

SECURITY AND PRIVACY AWARENESS TRAINING

We train our employees to be aware of the security and privacy risks associated with their roles and understand the applicable statutory, regulatory, and contractual compliance requirements related to the security and privacy of systems and data where they work. All new Certara employees receive essential security and privacy training, which is reinforced through mandatory annual supplemental training. We also conduct additional role-based training, as required. For example, our software developers need to know how to code securely, so we have developed a course to teach that.

5

SECURITY AND PRIVACY BY DESIGN AND DEFAULT

We employ a project management framework which includes the design and implementation of administrative, technical, and physical safeguards to protect personal data and considers the intended use of those data. We balance the need to process, collect, and store this information against any person's privacy risks. Our controls are commensurate with the risk and magnitude of the harm that would result from the unauthorized access, use, modification, loss or dissemination of the personal data we collect.

6

REGULATORY OBLIGATIONS

We use commercially reasonable efforts to protect personal information to the extent required by applicable data protection and privacy laws and regulations for locations where we conduct business and where our clients use our services. In certain circumstances, Certara may be obliged to disclose personal data under national or international law, or at the request of governmental agencies. We seek to comply with such requests, where doing so will not adversely impact peoples' privacy or materially affect business.

Corporate Governance and Compliance

DATA PRIVACY AND CYBERSECURITY

7

THIRD-PARTY CONTRACTUAL OBLIGATIONS

We include privacy requirements in our contracts, specifically in data protection agreements, approved standard contractual clauses, and other acquisition-related documents, which establish privacy roles and responsibilities for clients, contractors, service providers and third-party vendors.

8

DATA SECURITY GOVERNANCE

In most cases when we receive study data from our clients, they are pseudonymized (or key-coded) to mask the participants' identity. Pseudonymization techniques do not exempt Certara from data protection laws, however they do help us meet our data protection obligations.

We employ cryptographic technologies to protect sensitive business data against loss, unauthorized access, or disclosure. This applies to sensitive data, regardless of whether they are at rest or in transit.

We also have a formal process to guide our response to any incidents that impact information technology and service operations. This includes identification and analysis of known and, to the extent possible, suspected security and privacy-related incidents. The process provides direction for the containment, mitigation, and recovery from potentially harmful effects of incidents, and the formal documentation and communication of incidents and their outcomes.

As a testament to the success of this program, Certara has not experienced any reportable data breaches. We have not received any materially negative audit results or incurred any fines, and have promptly responded to all requests by individuals to delete their data.



Corporate Governance and Compliance

QUALITY PRODUCTS AND SERVICES

CERTARA CONTINUOUSLY AND INTENTIONALLY FOSTERS A CULTURE FOCUSED ON QUALITY.

Across every aspect of our operations, we believe that preventative action is far less risky, complex and costly than corrective action.

At Certara, we have implemented an electronic Quality Management System ("QMS"), TrackWise Digital ("TWD"), to provide an industry leading foundation for managing an effective QMS. The TWD system is a validated, 21 CFR Part 11 compliant QMS, which is used by all Certara business units. The Certara QMS serves as a document management solution for the review and approval of all policies, standard operating procedures, work instructions, forms and templates. It is also a training management system and serves as the repository for all training records on processes, as well as the home for corrective and preventative actions ("CAPAs"), audits (internal and external), quality events, and preventive actions and process deviation records.

The reporting functions of our QMS can produce real time and regular cadence reports on content such as training compliance across the entire company or by business unit, individual manager or employee. Likewise, CAPAs, audits, and other quality metrics are available in real time and at regular intervals as required.

Our clients routinely audit our systems and processes. During the last calendar year, we completed 56 customer audits, successfully leveraging our remote audit capability hosted by TWD. There have been no critical findings and auditors have commented on our clearly active, continuous improvement of our processes and regularly compliment us on the ease of use of our system.



"Across every aspect of our operations, we believe that preventative action is far less risky, complex and costly than corrective action."

– Jeff Schenk, Vice President, Quality Assurance



OUR QMS PRINCIPLES INCLUDE THE FOLLOWING:

- Certara's QMS serves as a central, electronic repository for all our enterprise-wide quality data. That enables us to access the information we need, when we need it.
- Our QMS facilitates this broad level of collaboration, serving as a single communication platform for all quality-related processes and information.
- Our QMS is configured to be user friendly for users throughout the enterprise.
- Our QMS features data segmentation, dashboards and reporting functions that allow users at all levels of the organization to gain meaningful insights into their operations for data-driven decision-making.
- We can track any CAPA full cycle from identification of the root cause, through actions taken to address it, to verification that the actions were effective.
- Our QMS is both flexible to adapt to changing demands, and scalable to meet growing needs.

Our Environmental Impact

CERTARA IS COMMITTED TO MINIMIZING ANY NEGATIVE IMPACTS OUR BUSINESS MAY HAVE ON THE ENVIRONMENT.

We strive to improve our environmental performance over time and to initiate projects and activities that will help preserve and protect our planet, and we will proactively demonstrate our commitment to stewardship and sustainable development. This commitment to the environment extends to our customers, our staff, and the community in which we operate.

As expressed in our Environmental Policy, we pledge to:

- Comply with all applicable environmental, health, and safety laws, regulations, and other requirements
- Prevent pollution whenever possible
- Continually improve our environmental performance
- Provide training to our employees on relevant environmental programs and empower them to contribute and participate
- Communicate our environmental commitment and efforts to our customers, staff, and community
- Implement effective waste minimization programs to reduce, reuse, and recycle materials and
- Continually improve over time by measuring our most significant environmental impacts.

Certara operates within a limited physical footprint, consisting of office-based facilities with no manufacturing operations. As of the end of 2021, we leased approximately 158,000 square feet of office space in 37 locations across the globe. Even before the COVID-19 pandemic, we allowed our employees great flexibility in working from home and had begun to reduce the number and size of our offices. We realized early in the pandemic that we can successfully operate in a virtual environment. However, we also believe there is great value in maintaining central hubs where our employees can meet together or with clients. We will continue to move toward a balance of minimizing our office footprint while ensuring our employees have convenient opportunities to collaborate and form strong bonds. We will continue to allow substantial flexibility in when and how frequently our employees commute to work, which we believe will further reduce our aggregate impact on the environment. We also track and analyze our office utilization to help us identify ways to reduce our total square footage, as well as minimize the energy and water consumption occurring at our facilities.

AVERAGE SQUARE FOOT/EMPLOYEE



2020
194
SF/EMPLOYEE

2021
158
SF/EMPLOYEE




Our Environmental Impact

We have a dedicated facilities management department that has introduced several programs intended to support our commitment to environmental stewardship:

- Paper recycling
- Use of water filter machines instead of water delivery systems
- Bulk purchases of office supplies to avoid multiple deliveries
- Discourage use of single use plastics by stocking kitchen spaces with full reusable (stainless) cutlery, dishes, glasses, etc.
- Supply coffee machines that use recyclable coffee pods
- Recycle or reuse of furniture, and donation of furniture where possible when vacating space
- Printers are set to "Print Both Sides" as default
- Notify building management on occupancy trends to allow for better utilization of the HVAC and electrical costs
- Transitioning from plastic security badges to utilizing electronic access applications and
- Recycling/donation of computer hardware, including laptops, monitors, keyboards, and docking stations.

Air travel by our employees is another important area where we believe we can have a positive impact on the environment. We began tracking this metric in 2019, but suspended air travel for most of 2020 and much of 2021 due to the COVID-19



pandemic. Although we expect our total miles flown will increase in 2022 over 2020 and 2021, our goal is to ensure that we limit air travel for business critical activities.

SUSTAINABLE PROCUREMENT

Certara believes that it is important for our vendors to share our commitment to sustainability, which is why we have adopted a Sustainable Procurement policy, through which we identify and manage the environmental, social, and economic impacts within our supply chain. More specifically, our policy dictates that we weigh the following factors when comparing and selecting material vendors:

- Does the supplier practice sustainable and ethical practices within their organization and drive such practices within their own supply chain?
- Does the supplier have programs in place that actively reduces their environmental footprint through conservation of resources, including the use of energy, water and materials?
- Can the supplier demonstrate how they reduce their carbon footprint through waste minimization, both within their operations and through reduction of packaging?
 - Does the supplier reduce the impact of deliveries by maximizing local sourcing?





**CERTARA REMAINS COMMITTED TO UNDERSTANDING, MONITORING, AND MANAGING
OUR SOCIAL AND ENVIRONMENTAL RESPONSIBILITIES AND DATA PRIVACY TO SUPPORT SUSTAINABLE GROWTH.**